STEPHEN HAHN to Time Factors
This is a "connection" page, showing publications STEPHEN HAHN has written about Time Factors.
Connection Strength
0.177
-
A phase I study of topical Tempol for the prevention of alopecia induced by whole brain radiotherapy. Clin Cancer Res. 2004 Oct 01; 10(19):6411-7.
Score: 0.023
-
A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin Cancer Res. 2004 Aug 15; 10(16):5447-54.
Score: 0.023
-
Patterns of recurrence in patients treated with photodynamic therapy for intraperitoneal carcinomatosis and sarcomatosis. Int J Oncol. 2004 Mar; 24(3):711-7.
Score: 0.022
-
Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. JAMA Netw Open. 2018 08 03; 1(4):e181390.
Score: 0.015
-
Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017 07 15; 98(4):900-907.
Score: 0.014
-
American Board of Radiology Maintenance of Certification Program: Evolution to Better Serve Stakeholders. Int J Radiat Oncol Biol Phys. 2016 Jan 01; 94(1):16-18.
Score: 0.013
-
A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme. J Neurooncol. 2014 Jan; 116(2):365-372.
Score: 0.011
-
Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2012 May; 93(5):1658-65; discussion 1665-7.
Score: 0.010
-
Tempol, a stable free radical, is a novel murine radiation protector. Cancer Res. 1992 Apr 01; 52(7):1750-3.
Score: 0.010
-
Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):e13-9.
Score: 0.010
-
Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen. Clin Cancer Res. 2008 Aug 01; 14(15):4869-76.
Score: 0.008
-
Optimization of light source parameters in the photodynamic therapy of heterogeneous prostate. Phys Med Biol. 2008 Aug 07; 53(15):4107-21.
Score: 0.008
-
Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res. 2004 Dec 15; 10(24):8177-84.
Score: 0.006
-
Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days. Clin Cancer Res. 2002 Aug; 8(8):2524-9.
Score: 0.005